Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists - Takeaways - MDSpire

Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists

  • By

  • Zayed Rashid

  • Selamawit Woldesenbet

  • Mujtaba Khalil

  • Abdullah Altaf

  • Shahzaib Zindani

  • Areesh Mevawalla

  • Azza Sarfraz

  • Khalid Mumtaz

  • Timothy M. Pawlik

  • February 26, 2026

  • 0 min

Share

  • 1

    Cancer is the second leading cause of death in the U.S., with over half a million annual cancer-related deaths.

  • 2

    GLP-1 receptor agonists (GLP-1 RAs) are used to manage diabetes and may influence cancer incidence through metabolic pathways.

  • 3

    Studies show mixed results regarding GLP-1 RAs and cancer risk, with some suggesting lower colorectal cancer incidence and others indicating potential thyroid cancer risk.

  • 4

    The study analyzed data from the IBM-MarketScan database, focusing on individuals diagnosed with type 2 diabetes between 2013 and 2021.

  • 5

    Outcomes included the incidence of various cancers, with patients followed for up to five years after their diabetes diagnosis.

Original Source(s)

Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists

  • by Zayed Rashid, Selamawit Woldesenbet, Mujtaba Khalil, Abdullah Altaf, Shahzaib Zindani, Areesh Mevawalla, Azza Sarfraz, Khalid Mumtaz, Timothy M. Pawlik

  • February 26, 2026

Related Content

Birthweight, Childhood BMI: What Drives the Link?

Mendelian randomization analyses linked higher birthweight with greater mid-childhood height but the connection could reflect genetic factors related to skeletal growth.

Impact of body mass index on outcomes of cardiac rehabilitation: a systematic review and meta-analysis

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.